Amgen got expanded FDA label approval for Uplizna

koto_feja Amgen ( NASDAQ: NASDAQ: AMGN ) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval for Uplizna, now approved as a treatment for immunoglobulin G4-related disease ((IgG4-RD)) in adults.

IgG4-RD is a chronic immune system disorder that.